SCHEMBL6874358

SCHEMBL6874358

N#Cc1c(O)cccc1I

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
MAPT P10636 3/20 0.41
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
CACNA1B Q00975 1/20 0.41
APBA1 Q02410 1/20 0.41
KMT2A Q03164 1/20 0.41
DYRK1A Q13627 3/20 0.40
SOS2 Q07890 1/20 0.37
TTR P02766 1/20 0.37
ALB P02768 1/20 0.37
EGFR P00533 2/20 0.36
CA2 P00918 2/20 0.36
LMNA P02545 2/20 0.36
FYN P06241 2/20 0.36
MMP9 P14780 2/20 0.36
HPGD P15428 2/20 0.36
ALOX15 P16050 2/20 0.36
RECQL P46063 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2285228 0.83 ALDH1A1 (0.50) ALDH1A1MAPTKDM4EMEN1GAA
SCHEMBL8466190 0.83 DYRK1A (0.46) ALDH1A1MAPTKDM4EMEN1GAA
SCHEMBL1285613 0.74 ALDH1A1 (0.43) ALDH1A1MAPTKDM4EMEN1GAA
SCHEMBL3957849 0.74 DYRK1A (0.47) ALDH1A1MAPTKDM4EMEN1GAA
SCHEMBL30473828 0.74 ALDH1A1 (0.43) ALDH1A1MAPTKDM4EMEN1GAA
SCHEMBL2336330 0.73 TSHR (0.50) ALDH1A1MAPTKDM4EMEN1GAA
SCHEMBL12845273 0.73 KDM4E (0.47) ALDH1A1MAPTKDM4EMEN1GAA
SCHEMBL1622559 0.73 ALOX15 (0.48) ALDH1A1MAPTKDM4EMEN1GAA
SCHEMBL421862 0.73 ALDH1A1 (0.43) ALDH1A1MAPTKDM4EMEN1GAA
SCHEMBL11876975 0.73 CYP1A2 (0.50) ALDH1A1MAPTKDM4EMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2323997-B1 PROCESSES AND INTERMEDIATES FOR MAKING SWEET TASTE ENHANCERS SENOMYX INC (US) 2017-09-06 EP disclosed
US-6812231-B2 INHIBITING ACTIVATED BLOOD-COAGULATION FACTOR X AJINOMOTO CO., INC. (JP) 2004-11-02 US disclosed
US-20020107290-A1 Benzamidine derivative AJINOMOTO CO., INC. (JP) 2002-08-08 US disclosed
US-6410538-B2 ANTICOAGULANT OR AN AGENT FOR TREATING OR PREVENTING THROMBI OR EMBOLI AJINOMOTO CO., INC. (JP) 2002-06-25 US disclosed
US-20010056123-A1 Anticoagulant or an agent for treating or preventing thrombi or emboli AJINOMOTO CO., INC (JP) 2001-12-27 US disclosed
CN-1311771-A Benzamidine derivative AJINOMOTO KK (JP) 2001-09-05 CN disclosed
EP-1086946-A1 BENZAMIDINE DERIVATIVE Ajinomoto Co., Inc. (JP) 2001-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107290-A1 Benzamidine derivative SERPINE1, SERPINC1, TFPI ALDH1A1 579/4885MAPT 4300/4885KDM4E 3660/4885
US-20010056123-A1 Anticoagulant or an agent for treating or preventing thrombi or emboli SERPINC1, SERPINE1, F2 ALDH1A1 1023/4885MAPT 4813/4885KDM4E 4253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.